GENEVA, Switzerland, Aug. 21 /PRNewswire/ -- Researchers at Selexis SA and The University of Lausanne have reported the identification of novel high-performance Genetic Elements also known as matrix attachment regions (or MARs). Data are presented using these novel high-performance Genetic Elements for increased gene expression in mammalian cells. This research, published online August 5 and in the September issue of the journal Nature Methods, demonstrates that using bioinformatics analysis, researchers computed putative novel genetic elements from the human genome and confirmed through cloning experiments that these newly identified genetic elements could significantly and stably increase transgene expression in mammalian cells when compared to previously known genetic elements.
"Having the ability to identify and apply the most powerful genetic elements for use in the rapid development of high-performance cell lines further improves our already powerful technology and service offering," said Dr. Igor Fisch, CEO of Selexis. "Selexis has been applying this experimental approach to identify of our most productive Selexis Genetic Elements, and in fact, we are planning the introduction of a new class of Selexis Genetic Elements later this year. These new elements will be smaller and more powerful and are showing even greater performance in boosting antibody expression in CHO cells," continued, Dr. Fisch. "We are confident our existing and new licensees and cell line development customers will benefit from this new offering."
About Selexis:
Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services to speed the development of high performance mammalian cell lines. The company's core intellectual property portfolio is based on the discovery and application of enabling genetic elements that control the dynamic organization of chromatin within all mammalian cells. Application of the Selexis Genetic Elements(TM) using the SURE Cell Line Development(SM) process has enabled the rapid development of high performance cell lines for a number of pharmaceutically important programs.
Selexis Genetic Elements(TM) and SURE Cell Line Development SM are trademarks of Selexis SA.
Selexis SACONTACT: Europe, Igor Fisch, Ph.D., Chief Executive Officer, +41 (0)22 30893 60, Igor.fisch@selexis.com, or United States, Andrew F. Sandford, VicePresident, Business Development and Licensing, +1-617-595-5769,andrew.sanford@selexis.com, both of Selexis SA
Web site: http://www.selexis.com/
